

# Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

## Strategic Trading Analysis

Based on the detailed analysis report for **AUROPHARMA.NS** (Aurobindo Pharma Ltd.) provided in the PDF, here is the positional trading assessment.

### Step 1: Audit the Data

- **Data Present:**
  - Price Action: Daily (3-year) and Weekly charts with candlestick classification.
  - Trend Indicators: EMAs (20, 50, 200), Supertrend, MACD.
  - Momentum/Volatility: RSI, Bollinger Bands, Volatility Squeeze, ATR.
  - Fundamentals: 4-year revenue/profit trends, ROE, Analyst estimates.
  - Relative Strength: Comparison against ^CNXPHARMA.
- **Data Missing:**
  - Institutional holding changes (FII/DII data) for the most recent quarter.
  - Specific option chain data (Open Interest buildup) to confirm support/resistance levels.
- **Confidence Level: High.** The technical and fundamental data provided is comprehensive enough to make a sound technical decision for an intermediate timeframe.

### Step 2: Analyze the Setup

- **Price Structure & Trend:**
  - **Bearish Short-Term:** The stock is currently trading at **1145.60**, which is below the 20 EMA (1169), 50 EMA (1174), and the 200 EMA (1161). This indicates significant overhead resistance. The price is currently trapped below a "knot" of moving averages.
  - **Bullish Support:** Despite trading below EMAs, the Supertrend (daily) is still Buy (Green) with support at **1119.77**. The weekly chart suggests the stock is resting near the 50-week EMA, acting as dynamic support.
- **Momentum:**
  - **Weak:** RSI is at 45.27 (Neutral-**Bearish**) and not showing strong divergence yet. MACD is in a bearish crossover state with momentum strengthening to the downside (Page 12).
  - **Relative Strength:** The stock is underperforming its sector (RS Score 49/100) and showing "Not Improving" performance (Page 4).
- **Volatility:**
  - Bollinger Bands are tightening (Width 0.10), indicating a potential squeeze. However, the price is in the *lower half* of the bands, suggesting the squeeze could resolve downwards or requires significant volume to reverse.
- **Candlestick Behavior:**
  - Recent "Buyer Control" signals (Page 20) and "Selling Exhaustion" (Page 18) suggest the downside momentum is slowing, but buyers have not yet reclaimed control of the trend.

### Step 3: Formulate the Recommendation

**Verdict: NO (Do not enter immediately)**

**Reasoning:** While the fundamentals are decent and the long-term trend (weekly) is intact, the immediate technical picture is fraught with resistance. Entering at **1145.60** puts you directly underneath a heavy

# Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

resistance cluster between **1160 and 1175** (the convergence of the 20, 50, and 200 EMAs). As a risk-averse trader, you should not buy *into* resistance while momentum (MACD/RSI) is negative. You need confirmation that the stock has reclaimed these averages.

## Conditional Plan (Watchlist for Breakout):

- **Condition to Buy:** The stock must register a **Daily Close above 1180**. This clears the EMA cluster (20, 50, 200) and confirms a return to bullish territory.
- **Entry Price: 1180 - 1185** (Buy Stop order or enter on the pullback after the close above 1180).
- **Stop Loss: 1115** (Daily Close basis). This is just below the current Supertrend support (1119) and recent consolidation lows.
  - *Risk: ~5.5%*
- **Take Profit:**
  - **Target 1: 1280** (Recent swing highs and Upper Bollinger Band resistance). ~8% gain.
  - **Target 2: 1340** (Analyst Consensus Target and long-term trend extension). ~13% gain.

**Summary:** The stock is currently in a "No Trade Zone." Buying now is catching a falling knife near support; wait for the reclaim of the 1180 level to ensure the intermediate trend has shifted back to bullish.

## Candlestick Classification Analysis

Based on the **Candlestick Classification System** provided in the report (specifically Pages 20 and 21), here is my analysis as a seasoned Price Action Trader.

### 1. Current Classification Snapshot

- **Latest Signal: Buyer Control (+1)**
- **Recent Trend Score (10-day avg): 0.00**
- **Dominant Market State: Indecision ("No Control")**

### 2. Interpreting the Price Action (Page 21)

**The "No Control" Plague (Context):** Looking at the chart on Page 21, the overwhelming number of **Grey candles (No Control)**-132 instances compared to 88 directional candles-tells me this stock is plagued by choppy, low-conviction trading. The algorithm defines "No Control" as small bodies with long wicks. This indicates that **institutions are not aggressively accumulating or distributing** at current levels; rather, the stock is drifting based on retail flow or general market noise.

**The Recent Swing (The "Seller Control" Wave):** Focus on the right side of the chart (Jan '26 - Feb '26). There was a distinct cluster of **Red candles (Seller Control)** that drove the price down from ~1240 to the current ~1145 level.\* *Algorithm Note:* These candles likely had moderate bearish bodies closing near their lows. The lack of "Strong Seller Control" (Dark Red) suggests this was a drift lower rather than a panic sell-off with massive volume.

**The Latest Candle (The "Buyer Control" Signal):** The most recent candle on the far right is **Light Green**

# Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

**(Buyer Control).**\* **Why it occurred:** According to your classification logic, this candle had a moderate bullish body (0.8-1.5 ATR) and likely closed in the upper half of its range.\* **Why it's NOT "Strong":** It failed to trigger the **Step 4 Volume Multiplier**. It likely did not have volume >1.3x average. This is critical. It means this bounce is **technical**, not necessarily institutional. It is a relief rally after the recent drop.

## 3. The "0.00" Trend Score Analysis

The 10-day average trend score is exactly **0.00**.\* This is a **Battleground / Equilibrium**.\* Over the last two weeks, the sum of Buyer signals (+1/+2) and Seller signals (-1/-2) has perfectly canceled out.\* In trading terms, the momentum has completely stalled. The sellers who drove it down from 1240 have exhausted their pressure, but buyers haven't shown up with enough force to reverse the trend yet.

## 4. Prediction & Strategy

### Verdict: Short-Term Technical Bounce within a Weak Structure

The appearance of a **Buyer Control (+1)** candle after a series of Seller candles, combined with a 0.00 trend score, usually marks a **temporary floor**.

**Prediction:** I expect the price to attempt a minor bounce or consolidation from the **1145** level. The "Buyer Control" signal suggests the immediate selling pressure has lifted.

**Key Levels to Watch:**\* **Upside (Resistance):** Watch for the price to retest the **1175-1200** zone. Unless we see a **Buyer Strong Control (+2)** candle (Large Green Body + High Volume) appear, this rally is likely to fail and result in more "No Control" chopping.\* **Downside (Support):** The 1120 level is critical. If we see a **Seller Strong Control (-2)** candle close below 1140, the equilibrium (0.00 score) will break, and the trend will resume downward.

**Trader's Take:** Because the 10-day score is 0.00 and the volume didn't trigger a "Strong" rating on the buy signal, **I would not treat this as a high-conviction reversal buy**. It is merely a pause. I would wait for a **"Step 4" confirmation**-a candle where volume spikes >1.3x average-before assuming the buyers have actually taken control of the trend.

# News & Analyst Targets

As of mid-February 2026, here is the latest research and information regarding **Aurobindo Pharma (AUROPHARMA)**.

## 1) Latest News for AUROPHARMA (Week of Feb 10, 2026)

The stock has been under pressure this week due to regulatory setbacks, despite reporting steady quarterly earnings.

# Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

- **USFDA Regulatory Setbacks:** The biggest negative catalyst this week was the **USFDA issuing a Form 483 with 9 observations** to the company's **Unit-VII** facility in Telangana following an inspection from Jan 28 to Feb 10, 2026. This comes shortly after its subsidiary **Eugia Pharma (Unit-III)** received **11 observations** earlier in the month, raising concerns about prolonged regulatory hurdles.
- **Q3 FY26 Earnings Results:** On Feb 10, the company reported its Q3 numbers.
  - **Net Profit:** Rose ~8% YoY to **INR 910 crore**, slightly missing some street estimates.
  - **Revenue:** Grew **8.4% YoY** to **INR 8,646 crore**, driven by strong performance in the **European market (+27%)** and ARV segment.
  - **US Business:** Sales were soft (down ~3.4% YoY to \$420M) due to the absence of gRevlimid contribution, though the base business remained stable.
- **New Product Approval:** On Feb 13, its subsidiary Acrotech Biopharma received **USFDA approval** for **ADQUEY (difamilast) ointment**, a treatment for atopic dermatitis.
- **Stock Reaction:** Shares fell approximately **8%** early in the week following the double whammy of USFDA observations and the earnings report.

## 2) Brokerage Upgrades & Downgrades

- **Downgrades/Negative Views:**
  - **Citi** maintained its **Sell** rating, citing concerns over the USFDA observations and valuation.
  - **MarketsMojo** has a **Hold** rating (downgraded from Buy in Dec 2025) and recently noted the valuation has shifted from "Attractive" to "Fair."
- **Upgrades/Reiterations:**
  - Most domestic brokerages (like **ICICI Securities**, **Axis Direct**, **Motilal Oswal**) have **maintained their BUY** ratings but have adjusted their target prices to reflect the regulatory risks and Q3 performance. They view the correction as an opportunity, betting on the Europe business and future biosimilar launches.

## 3) Indirect News Impacting AUROPHARMA

- **US Generic Pricing Pressure:** Industry reports from this week highlight that pricing pressure in the US generic market remains a "weak spot" for Indian pharma. While price erosion is stabilizing, it hasn't bottomed out, which limits margin expansion for Aurobindo's core US business.
- **Sector-Wide Regulatory Scrutiny:** The USFDA has ramped up inspections across Indian manufacturing sites in 2026. With Aurobindo receiving observations at two key units back-to-back, it highlights a broader sector risk of stricter compliance enforcement.
- **Lannett Acquisition:** Analysts are closely watching the completion of the **Lannett acquisition** (expected Q1 FY27), which is anticipated to add ~7% to US revenue growth and help diversify the portfolio.

## 4) Latest Analyst Targets (Post-Q3 FY26 Results)

Below is a summary of the latest price targets released by major brokerages after the Q3 earnings announcement on Feb 10-11, 2026.

Brokerage Firm	Rating	Target Price (INR )	Outlook / Key Rationale
ICICI Securities	Buy	1,490	<b>Strong Europe growth &amp; stable margin guidance (20-21%).</b> <b>Long-term growth intact despite near-term regulatory noise.</b> <b>Valuations attractive; expects 15% earnings CAGR over FY26-28.</b>
BofA Securities	Buy	1,440	
Motilal Oswal	Buy	1,430	

# Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

Brokerage Firm	Rating	Target Price (INR )	Outlook / Key Rationale
Investec	Buy	1,425	Positive on complex generic pipeline and capacity expansion.
HSBC	Buy	1,380	Maintained Buy; focuses on recovery in US base business.
Axis Direct	Buy	1,345	Good traction in Europe/Growth markets offsets US weakness.
Goldman Sachs	Buy	1,325	Adjusted target slightly; sees value emerging after correction.
BOB Capital	Buy	1,294	Q3 was in-line; Europe remains the key growth driver.
Citi	Sell	1,020	Concerns over USFDA observations at Unit-VII & Eugia Unit-III.

Note: Share price as of mid-February 2026 is trading in the INR 1,130 - INR 1,160 range.


# Stock Detailed Analysis Report

**AUROPHARMA.NS**

Current Price: ₹1145.60

Generated: 2026-02-14 10:12

# AUROPHARMA.NS - 3 Year Daily Price Chart



# Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	9.31%	10.33%
Net Income	Yes	Yes	9.86%	9.59%
ROE	No	Yes	0.41%	-0.31%
EPS	Yes	Yes	10.43%	9.79%

# Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	10.43%	3.20%
Net Income	Yes	10.37%	2.99%
ROE	Yes	4.52%	4.52%
EPS	Yes	10.35%	1.19%



# AUROPHARMA.NS - Relative Strength Analysis

## == OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	<b>Neutral</b>
RS Score:	49.6/100

:

## == RS RATIOS ==:

1M RS:	<b>0.997 [Neutral]</b>
3M RS:	<b>0.964 [Neutral]</b>
6M RS:	<b>1.049 [Leader]</b>
1Y RS:	<b>0.945 [Neutral]</b>

:

## == TURNAROUND ANALYSIS ==:

Turnaround Status:	<b>Not Detected</b>
--------------------	---------------------


:

## SIGNAL CRITERIA::


✓ Emerging RS:	1M (0.997) > 3M (0.964)
✓ Medium-term Lagging:	1Y=0.945 ( $\leq 1.0$ )
✗ Performance Improving:	<b>Not improving</b>

Relative Strength Analysis: AUROPHARMA.NS vs ^CNXPHARMA  
Classification: Neutral


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)



RS Composite Score Timeline



## AUROPHARMA.NS - EMA Crossover Summary

EMA 20:	1169.67
EMA 50:	1174.52
EMA 200:	1161.73
Trend Status:	<b>Short-term Downtrend</b>
Golden Cross Date:	2025-11-26 00:00:00+05:30
Golden Cross Price:	1227.40


AUROPHARMA.NS EMA Crossover Analysis



## AUROPHARMA.NS - Bollinger Bands Summary

<b>Current Price:</b>	1145.60
<b>Upper Band:</b>	1226.26
<b>Middle Band (SMA 20):</b>	1163.48
<b>Lower Band:</b>	1100.71
<b>%B:</b>	0.3576
<b>Band Width:</b>	0.1079
<b>Status:</b>	Lower Half
<b>Signal:</b>	None


AUROPHARMA.NS Bollinger Bands (20, 2) Analysis



## AUROPHARMA.NS - Supertrend Summary

Status:	<b>UPTREND (Buy)</b>
Supertrend Value:	1119.77
Signal Identified On:	2026-02-03

Supertrend Analysis for AUROPHARMA.NS (Period: 14, Multiplier: 3.0, Interval: 1d)






## AUROPHARMA.NS - MACD Summary

MACD Line:	-6.69
Signal Line:	-4.36
Histogram:	-2.33
Trend:	<b>Bearish</b>
Momentum:	<b>Strengthening</b>
Signal:	None

AUROPHARMA.NS Price






AUROPHARMA.NS MACD (12, 26, 9)



## AUROPHARMA.NS - Volatility Squeeze Summary

<b>BB Width:</b>	0.1079
<b>ATR:</b>	47.0429
<b>Total Signals:</b>	29
<b>Signal 1:</b>	BB Squeeze at 2026-01-08 00:00:00+05:30 (Price: 1206.10)
<b>Signal 2:</b>	BB Squeeze at 2026-01-09 00:00:00+05:30 (Price: 1198.70)
<b>Signal 3:</b>	BB Squeeze at 2026-01-12 00:00:00+05:30 (Price: 1172.90)
<b>Signal 4:</b>	BB Squeeze at 2026-01-13 00:00:00+05:30 (Price: 1167.70)
<b>Signal 5:</b>	BB Squeeze at 2026-01-14 00:00:00+05:30 (Price: 1180.10)

# AUROPHARMA.NS - Volatility Squeeze Analysis



# AUROPHARMA.NS - RSI-Volume Summary

Current RSI:	45.27
Current Volume:	1682470
Volume MA 20:	1872473
Bullish Divergences:	1
Bearish Divergences:	3
Bullish Div 1:	Date: 2025-02-03 00:00:00+05:30, Price: 1121.19
Bearish Div 1:	Date: 2024-08-30 00:00:00+05:30, Price: 1563.53
Bearish Div 2:	Date: 2025-10-13 00:00:00+05:30, Price: 1136.80

# AUROPHARMA.NS RSI-Volume Divergence Analysis



# AUROPHARMA.NS - Volume Analysis

## == VOLUME ANALYSIS ==:

Status:

**30 Signals Detected**

:

**2026-01-09 [-]:**

Distribution Day

**2026-01-16 [-]:**

Distribution Day

**2026-01-21 [+]:**

**Selling Exhaustion (Bullish Div)**



**2026-02-03 [-]:**

Climax Volume (Churning)

**2026-02-04 [-]:**

Distribution Day

# AUROPHARMA.NS - Volume Analysis





# AUROPHARMA.NS - Candlestick Classification Summary

== CANDLESTICK CLASSIFICATION ==:

Latest Classification: **Buyer Control**

Recent Trend Score (10-day avg): 0.00

:

Distribution:

No Control: 132

Seller Control: 51

Buyer Control: 37

Seller Strong Control: 4

Buyer Strong Control: 3

# AUROPHARMA.NS - Candlestick Classification




## Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	UPTREND (Buy)	1122.17	1145.6	2025-11-10
1 Day	UPTREND (Buy)	1119.77	1145.6	2026-02-03
15 Min	UPTREND (Buy)	1131.77	1157.0	2026-02-13

## Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bearish	Strengthening	No Signal
1 Day	Bearish	Strengthening	No Signal
15 Min	Bullish	Strengthening	Bullish Crossover (Buy)

AUROPHARMA.NS - 1 Week (Candlestick + EMAs)




AUROPHARMA.NS - 1 Day (Candlestick + EMAs)



AUROPHARMA.NS - 15 Min (Candlestick + EMAs)



## Trendlyne Snapshot - AUROPHARMA\_main



## Trendlyne Snapshot - AUROPHARMA\_forecaster

Markets

STARFOLIO

Alerts

F&O

MF

Reports

Screeners

Subscribe

Superstars

Portfolio

Watchlist

Insider Trades

Results

Data Downloader

More

Search Stock, IPO, MF

India

A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / AUROBINDO PHARMA LTD.

Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804

Mid-range Performer

In 4 Starfolio Baskets

1145.60

-12.30 (-1.06%)

1.7M

NSE+BSE Volume

NSE 13 Feb, 2026 3:31 PM (IST)

Watchlist

Portfolio

Alert

My Notes

TRADE STOCK

Analyst Buy

Axis Direct retains a 'Buy' call on Aurobindo Pharma, expects a revenue CAGR of 16.5% over FY26-28

See details

Overview

FORECASTER

STOCK REPORT

Buy Sell Zone

F&O

Financials

News

Reports

Technicals

Shareholding

Deals

Corporate Actions

Alerts

About

### Aurobindo Pharma - AUROPHARMA - stock price prediction, stock forecast, target price, analyst ratings from 26 analysts

Aurobindo Pharma has a share price target of Rs 1344, revenue growth forecast of 5.3%, and profit growth estimate of 3.2% for FY26, based on top 26 analyst calls.

### Aurobindo Pharma FORECASTER - Analyst Estimates

[FORECASTER DASHBOARD](#)